Neoplasm News and Research

RSS

Neoplasm is an abnormal mass of tissue as a result of neoplasia.

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Celgene International Sàrl today announced that results from a clinical study of ABRAXANE in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.

7 Oct 2011

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte Corporation announced today additional symptom improvement and quality of life (QoL) results from COMFORT-I, a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with myelofibrosis (MF).

13 Jun 2011

Survivors of childhood cancer at increased risk of developing subsequent primary neoplasms

In a study that included nearly 18,000 children who had cancer, with follow-up of about 25 years, the greatest excess risk associated with a subsequent primary neoplasm (a new tumor) at older than age 40 years was for digestive and genitourinary neoplasms (related to the genital or urinary tract organs), according to a study in the June 8 issue of JAMA, a theme issue on cancer.

7 Jun 2011

GSK receives FDA approval for Lamictal XR to treat partial seizures

GlaxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal XR Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug.

26 Apr 2011

Asuragen launches InformThyroid, a panel of molecular markers

Asuragen, Inc. announced today the launch of Inform™Thyroid, a panel of molecular markers used on Fine Needle Aspirates (FNA) of thyroid nodules to aid physicians in the management of thyroid cancer.

6 Apr 2011

Postdoctoral research fellows receive Pancan- AACR Pathway to Leadership Grants

The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Jennifer M. Bailey, Ph.D., and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic Cancer Action Network - AACR Pathway to Leadership Grants.

9 Mar 2011

Overexpression of microRNA 125b can cause leukemia: Research

Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).

30 Nov 2010

Gefitinib exhibits potential as chemoprevention agent for pancreatic cancer

Gefitinib may be a promising chemoprevention agent for pancreatic cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

9 Nov 2010

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Genentech, Inc., a member of the Roche Group today announced updated data from a Phase III study (ROSE) that showed rheumatoid arthritis (RA) patients receiving ACTEMRA (tocilizumab) experienced a rapid, measured response as early as one week after beginning ACTEMRA, and improvement in disease activity within four weeks.

8 Nov 2010

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Antigenics, Inc. today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage® vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.

25 Oct 2010

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Incyte Corporation, Results from a Phase I/II study of Incyte's janus kinase (JAK) inhibitor with the investigational name INCB18424 (also known as INCB018424 and INC424) were published today in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis.

16 Sep 2010

BioCryst reports results from forodesine studies for CTCL and CLL

BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).

15 Sep 2010

Survival rates of nine types of cancer in Spain

Spanish epidemiologists have presented information on survival of nine types of cancer in Spain and have compared it with other European countries. At five years from diagnosis, the lowest survival rate is observed in lung cancer (less than 11%), and the highest in testicular cancer (95%). Cancer survival in Spain is at the European average.

16 Jul 2010

Experts to discuss latest trends in treatments, diagnostic techniques for managing HCC

Today, world renowned experts have assembled in Dubrovnik, Croatia to discuss the latest trends in treatment and cutting edge research in diagnostic techniques that will shape the future management of hepatocellular carcinoma - the third most common cause of cancer-related death globally, and a leading cause of death among patients with liver cirrhosis.

28 Jun 2010

Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

Inflammatory myofibroblastic tumor (IMT) is an uncommon benign neoplasm with locally aggressive behavior but malignant change is rare. Such a rare tumor occurring in a 14-year-old patient with clinical presentations of abdominal pain and body weight loss was seldom described before.

18 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

ASGE issues guidelines on ethnicity, gastrointestinal diseases and endoscopic procedures

The American Society for Gastrointestinal Endoscopy (ASGE) has issued guidelines addressing ethnicity, gastrointestinal diseases and endoscopic procedures. The guideline suggests that colorectal cancer screening should begin at age 45 for average risk African-American men and women, and that it is recommended that colorectal cancer screening be emphasized for other minority ethnic groups that have lower screening utilization rates.

4 Jun 2010

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Toxcure, LLC, an emerging specialty biopharmaceutical company, today announced the grant of U.S. Patent No. 7,709,440, which provides Toxcure with intellectual property protection for a method of treating various tumors with neurotoxins.

21 May 2010

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Antigenics today announced that data from a multi-center Phase 1/2 clinical trial of Oncophage (vitespen) for recurrent high-grade glioma (brain cancer) was presented at the International Conference on Brain Tumor Research and Therapy. The study was conducted by the Brain Tumor Research Center at the University of California, San Francisco.

20 May 2010

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

Keryx Biopharmaceuticals today announced the publication of an article in the May 12th Journal of the National Cancer Institute, entitled "In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine," demonstrating the single agent activity of KRX-0401 (perifosine) in neuroblastoma tumor preclinical models.

18 May 2010